Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Inhibition of mitochondrial dynamics preferentially targets pancreatic cancer cells with enhanced tumorigenic and invasive potential

  • Courtois, Sarah
  • de Luxán-Delgado, Beatriz
  • Penin-Peyta, Laure
  • Royo-García, Alba
  • Parejo-Alonso, Beatriz
  • Jagust, Petra
  • Alcalá, Sonia
  • Rubiolo, Juan A.
  • Sánchez, Laura
  • Sainz, Bruno
  • Heeschen, Christopher
  • Sancho, Patricia
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, partly due to its intrinsic aggressiveness, metastatic potential, and chemoresistance of the contained cancer stem cells (CSCs). Pancreatic CSCs strongly rely on mitochondrial metabolism to maintain their stemness, therefore representing a putative target for their elimination. Since mitochondrial homeostasis de-pends on the tightly controlled balance between fusion and fission processes, namely mitochondrial dynamics, we aim to study this mechanism in the context of stemness. In human PDAC tissues, the mitochondrial fission gene DNM1L (DRP1) was overexpressed and positively correlated with the stemness signature. Moreover, we observe that primary human CSCs display smaller mitochondria and a higher DRP1/MFN2 expression ratio, indicating the activation of the mitochondrial fission. In-terestingly, treatment with the DRP1 inhibitor mDivi-1 induced dose-dependent apoptosis, especially in CD133+ CSCs, due to the accumulation of dysfunctional mitochondria and the subsequent energy crisis in this subpopulation. Mechanistically, mDivi-1 inhibited stemness-related features, such as self-renewal, tumorigenicity, and invasiveness and chemosensitized the cells to the cytotoxic effects of Gemcitabine. In summary, mitochondrial fission is an essential process for pancreatic CSCs and represents an attractive target for designing novel multimodal treatments that will more efficiently eliminate cells with high tumorigenic potential, This research was funded by the Pancreatic Cancer Research Fund, 2015 Award Round (P.S., C.H.); the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n 602783 (CAM-PaC) (C.H.), theWorldwide Cancer Research Charity together with Fundación Científica Asociación Española contra el Cáncer (FCAECC) (19-0250) (P.S.); A Fero Foundation grant and a Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC) (B.S.J.); and the Instituto de Salud Carlos III through the Miguel Servet Program (CP16/00121) and Fondo de Investigaciones Sanitarias (PI17/00082) (both co-financed by European funds (FSE: “El FSE invierte en tu futuro” and FEDER: “Una manera de hacer Europa,” respectively) (P.S.)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk

  • Gomez-Rubio, P.
  • Piñero González, Janet, 1977-
  • Ilzarbe Sánchez, Lucas
  • Iglesias Coma, Mar
  • Poves Prim, José Ignacio
  • Real, Francisco X.
  • PanGenEU Study Investigators
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, many patients suffer or have suffered from other diseases. Identifying disease patterns associated with PDAC risk may enable a better characterization of high-risk patients. METHODS: Multimorbidity patterns (MPs) were assessed from 17 self-reported conditions using hierarchical clustering, principal component, and factor analyses in 1705 PDAC cases and 1084 controls from a European population. Their association with PDAC was evaluated using adjusted logistic regression models. Time since diagnosis of morbidities to PDAC diagnosis/recruitment was stratified into recent (<3 years) and long term (≥3 years). The MPs and PDAC genetic networks were explored with DisGeNET bioinformatics-tool which focuses on gene-diseases associations available in curated databases. RESULTS: Three MPs were observed: gastric (heartburn, acid regurgitation, Helicobacter pylori infection, and ulcer), metabolic syndrome (obesity, type-2 diabetes, hypercholesterolemia, and hypertension), and atopic (nasal allergies, skin allergies, and asthma). Strong associations with PDAC were observed for ≥2 recently diagnosed gastric conditions [odds ratio (OR), 6.13; 95% confidence interval CI 3.01-12.5)] and for ≥3 recently diagnosed metabolic syndrome conditions (OR, 1.61; 95% CI 1.11-2.35). Atopic conditions were negatively associated with PDAC (high adherence score OR for tertile III, 0.45; 95% CI, 0.36-0.55). Combining type-2 diabetes with gastric MP resulted in higher PDAC risk for recent (OR, 7.89; 95% CI 3.9-16.1) and long-term diagnosed conditions (OR, 1.86; 95% CI 1.29-2.67). A common genetic basis between MPs and PDAC was observed in the bioinformatics analysis. CONCLUSIONS: Specific multimorbidities aggregate and associate with PDAC in a time-dependent manner. A better characterization of a high-risk population for PDAC may help in the early diagnosis of this cancer. The common genetic basis between MP and PDAC points to a mechanistic link between these conditions., The work was partially supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III-FEDER, Spain (PI11/01542, PI0902102, PI12/01635, PI12/00815, PI13/00082, and CP10/00524); Red Tematica de Investigacion Cooperativa en Cancer, Spain (RD12/0036/0034, RD12/0036/0050, and RD12/0036/0073); World Cancer Research (WCR 15-0391); Accion Especial de Gen omica, Spain (GEN2001-4748-c05-03); EU-6FP Integrated Project (018771-MOLDIAG-PACA), EUFP7-HEALTH (259737-CANCERALIA, 256974-EPC-TM-Net, and 602783-Cam-Pac), Associazione Italiana Ricerca sul Cancro (AIRC 12182); Cancer Focus Northern Ireland and Department for Employment and Learning; ALF (SLL20130022), Sweden; Italian Foundation for Cancer Research (FIRC) (no grant numbers apply). The
Repisalud
Publicación Artículo científico (JournalArticle)

MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3

  • Cioffi, Michele
  • Vallespinos-Serrano, Mireia
  • Trabulo, Sara M.
  • Jose Fernandez-Marcos, Pablo
  • Firment, Ashley N.
  • Vazquez, Berta N.
  • Vieira, Catarina R.
  • Mulero, Francisca
  • Camara, Juan A.
  • Cronin, Ultan P.
  • Perez, Manuel
  • Soriano, Joaquim
  • Galvez, Beatriz G.
  • Castells-Garcia, Alvaro
  • Haage, Verena
  • Raj, Deepak
  • Megias Vazquez, Diego
  • Hahn, Stephan
  • Serrano, Lourdes
  • Moon, Anne
  • Aicher, Alexandra
  • Heeschen, Christopher
Conquering obesity has become a major socioeconomic challenge. Here, we show that reduced expression of the miR-25-93-106b cluster, or miR-93 alone, increases fat mass and, subsequently, insulin resistance. Mechanistically, we discovered an intricate interplay between enhanced adipocyte precursor turnover and increased adipogenesis. First, miR-93 controls Tbx3, thereby limiting self-renewal in early adipocyte precursors. Second, miR-93 inhibits the metabolic target Sirt7, which we identified as a major driver of in vivo adipogenesis via induction of differentiation and maturation of early adipocyte precursors. Using mouse parabiosis, obesity in mir-25-93-106b(-/-) mice could be rescued by restoring levels of circulating miRNA and subsequent inhibition of Tbx3 and Sirt7. Downregulation of miR-93 also occurred in obese ob/ob mice, and this phenocopy of mir-25-93-106b(-/-) was partially reversible with injection of miR-93 mimics. Our data establish miR-93 as a negative regulator of adipogenesis and a potential therapeutic option for obesity and the metabolic syndrome.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Inhibition of Mitochondrial Dynamics Preferentially Targets Pancreatic Cancer Cells with Enhanced Tumorigenic and Invasive Potential

  • Courtois, Sarah
  • Luxán Delgado, Beatriz de
  • Penin Peyta, Laure
  • Royo García, Alba
  • Pareja Alonso, Beatriz
  • Jagust, Petra
  • Alcalá, Sonia
  • Rubiolo Gaytán, Juan Andrés
  • Sánchez Piñón, Laura
  • Sainz Anding, Bruno
  • Heeschen, Christopher
  • Sancho, Patricia
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors, partly due to its intrinsic aggressiveness, metastatic potential, and chemoresistance of the contained cancer stem cells (CSCs). Pancreatic CSCs strongly rely on mitochondrial metabolism to maintain their stemness, therefore representing a putative target for their elimination. Since mitochondrial homeostasis depends on the tightly controlled balance between fusion and fission processes, namely mitochondrial dynamics, we aim to study this mechanism in the context of stemness. In human PDAC tissues, the mitochondrial fission gene DNM1L (DRP1) was overexpressed and positively correlated with the stemness signature. Moreover, we observe that primary human CSCs display smaller mitochondria and a higher DRP1/MFN2 expression ratio, indicating the activation of the mitochondrial fission. Interestingly, treatment with the DRP1 inhibitor mDivi-1 induced dose-dependent apoptosis, especially in CD133+ CSCs, due to the accumulation of dysfunctional mitochondria and the subsequent energy crisis in this subpopulation. Mechanistically, mDivi-1 inhibited stemness-related features, such as self-renewal, tumorigenicity, and invasiveness and chemosensitized the cells to the cytotoxic effects of Gemcitabine. In summary, mitochondrial fission is an essential process for pancreatic CSCs and represents an attractive target for designing novel multimodal treatments that will more efficiently eliminate cells with high tumorigenic potential
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNMT1 inhibition reprograms pancreatic cancer stem cells via upregulation of the miR-17-92 cluster

  • Zagorac, Sladjana
  • Alcalá, Sonia
  • Fraga, Mario F.
  • Heeschen, Christopher
  • Sainz, Bruno Jr.
PMCID: PMC5295626.-- et al., Pancreatic ductal adenocarcinoma (PDAC) and other carcinomas are hierarchically organized, with cancer stem cells (CSC) residing at the top of the hierarchy, where they drive tumor progression, metastasis, and chemoresistance. As CSC and non-CSC share an identical genetic background, we hypothesize that differences in epigenetics account for the striking functional differences between these two cell populations. Epigenetic mechanisms, such as DNA methylation, play an important role in maintaining pluripotency and regulating the differentiation of stem cells, but the role of DNA methylation in pancreatic CSC is obscure. In this study, we investigated the genome-wide DNA methylation profile of PDAC CSC, and we determined the importance of DNA methyltransferases for CSC maintenance and tumorigenicity. Using high-throughput methylation analysis, we discovered that sorted CSCs have a higher level of DNA methylation, regardless of the heterogeneity or polyclonality of the CSC populations present in the tumors analyzed. Mechanistically, CSC expressed higher DNMT1 levels than non-CSC. Pharmacologic or genetic targeting of DNMT1 in CSCs reduced their self-renewal and in vivo tumorigenic potential, defining DNMT1 as a candidate CSC therapeutic target. The inhibitory effect we observed was mediated in part through epigenetic reactivation of previously silenced miRNAs, in particular the miR-17-92 cluster. Together, our findings indicate that DNA methylation plays an important role in CSC biology and also provide a rationale to develop epigenetic modulators to target CSC plasticity and improve the poor outcome of PDAC patients., This research was supported by the ERC Advanced Investigator Grant (Pa-CSC 233460 to C. Heeschen) and the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 256974 (EPC-TM-NET; to C. Heeschen) and no. 602783 (CAM-PaC; to C. Heeschen), the 2015 SU2C Lustgarten CRUK Pancreatic Cancer Dream Team Award (C. Heeschen), Pancreatic Cancer UK RIF2014_04 and RIF2015_03 (both to C. Heeschen), a Rámon y Cajal Merit Award from the Ministerio de Economía y Competitividad, Spain (B. Sainz Jr), a Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (B. Sainz Jr), and a Proyecto de Investigación de Salud, ISCIII, Spain (no. PI15/01507 to B. Sainz Jr)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MEK inhibition targets cancer stem cells and impedes migration of pancreatic cancer cells in vitro and in vivo

  • Walter, Karolin
  • Tiwary, Kanishka
  • Trajkovic-Arsic, Marija
  • Hidalgo-Sastre, Ana
  • Dierichs, Laura
  • Liffers, Sven T.
  • Gu, Jiangning
  • Gout, Johann
  • Schulte, Lucas-Alexander
  • Münch, Jan
  • Seufferlein, Thomas
  • Sainz, Bruno Jr.
  • Siveke, Jens T.
  • Rodriguez-Aznar, Eva
  • Hermann, Patrick C.
Pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease with a very poor prognosis. At the same time, its incidence is on the rise, and PDAC is expected to become the second leading cause of cancer-related death by 2030. Despite extensive work on new therapeutic approaches, the median overall survival is only 6-12 months after diagnosis and the 5-year survival is less than 7%. While pancreatic cancer is particularly difficult to treat, patients usually succumb not to the growth of the primary tumor, but to extensive metastasis; therefore, strategies to reduce the migratory and metastatic capacity of pancreatic cancer cells merit close attention. The vast majority of pancreatic cancers harbor RAS mutations. The outstanding relevance of the RAS/MEK/ERK pathway in pancreatic cancer biology has been extensively shown previously. Due to their high dependency on Ras mutations, pancreatic cancers might be particularly sensitive to inhibitors acting downstream of Ras. Herein, we use a genetically engineered mouse model of pancreatic cancer and primary pancreatic cancer cells were derived from this model to demonstrate that small-molecule MEK inhibitors functionally abrogate cancer stem cell populations as demonstrated by reduced sphere and organoid formation capacity. Furthermore, we demonstrate that MEK inhibition suppresses TGFβ-induced epithelial-to-mesenchymal transition and migration in vitro and ultimately results in a highly significant reduction in circulating tumor cells in mice., P.C.H. is supported by a Max Eder Fellowship of the German Cancer Aid (111746) and by a Hector Foundation Cancer Research grant (M65.1). P.C.H. and J.M. are supported by a Collaborative Research Centre grant of the German Research Foundation (316249678–SFB 1279). J.T.S. is supported by the European Union Framework Programme 7 for research, technological development, and demonstration (FP7/CAM-PaC) under grant agreement no. 602783, the German Cancer Consortium (DKTK), and the Deutsche Forschungsgemeinschaft (DFG; KFO337/SI 1549/3-1). B.S., Jr., was funded by a Rámon y Cajal Merit Award from the Ministerio de Economía y Competitividad, Spain, and a coordinated grant from the Fundación Asociación Española Contra el Cáncer (AECC, GC16173694BARB)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The anthrax toxin receptor 1 (ANTXR1) is enriched in pancreatic cancer stem cells derived from primary tumor cultures

  • Alcalá, Sonia
  • Martinelli, Paola
  • Hermann, Patrick C.
  • Heeschen, Christopher
  • Sainz, Bruno Jr.
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related mortality. Cancer stem cells (CSCs) have been shown to be the drivers of pancreatic tumor growth, metastasis, and chemoresistance, but our understanding of these cells is still limited by our inability to efficiently identify and isolate them. While a number of markers capable of identifying pancreatic CSCs (PaCSCs) have been discovered since 2007, there is no doubt that more markers are still needed. The anthrax toxin receptor 1 (ANTXR1) was identified as a functional biomarker of triple-negative breast CSCs, and PDAC patients stratified based on ANTXR1 expression levels showed increased mortality and enrichment of pathways known to be necessary for CSC biology, including TGF-β, NOTCH, Wnt/β-catenin, and IL-6/JAK/STAT3 signaling and epithelial to mesenchymal transition, suggesting that ANTXR1 may represent a putative PaCSC marker. In this study, we show that ANTXR1+ cells are not only detectable across a panel of 7 PDAC patient-derived xenograft primary cultures but ANTXR1 expression significantly increased in CSC-enriched 3D sphere cultures. Importantly, ANTXR1+ cells also coexpressed other known PaCSC markers such as CD44, CD133, and autofluorescence, and ANTXR1+ cells displayed enhanced CSC functional and molecular properties, including increased self-renewal and expression of pluripotency-associated genes, compared to ANTXR1- cells. Thus, this study validates ANTXR1 as a new PaCSC marker and we propose its use in identifying CSCs in this tumor type and its exploitation in the development of CSC-targeted therapies for PDAC., The research was supported by a Ramón y Cajal Merit Award from the Ministerio de Economía y Competitividad, Spain (BS, Jr.); a coordinated grant from the Fundación Científica Asociación Española Contra el Cáncer (AECC, GC16173694BARB) (BS, Jr.); a Fondo de Investigaciones Sanitarias (FIS) grant PI15/01507 (BS, Jr.) (cofinanced through Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”) from the Instituto de Salud Carlos III (ISCIII), Spain; the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 602783 (CAM-PaC) (CH) and UNSW SHARP Seed Funding (CH); a Max Eder Fellowship of the German Cancer Aid (111746) (PCH); the German Research Foundation (DFG, CRC 1279 “Exploiting the Human Peptidome for Novel Antimicrobial and Anticancer Agents”) (PCH); the Austrian Science Fund (FWF-B27361) (PM); and Ingrid Shaker-Nessmann Foundation for Cancer Research (PM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells

  • Jagust, Petra
  • Alcalá, Sonia
  • Sainz, Bruno Jr.
  • Heeschen, Christopher
  • Sancho, Patricia
©The Author(s) 2020., [Background]:Cellular metabolism regulates stemness in health and disease. A reduced redox state is essential for self-renewal of normal and cancer stem cells (CSCs). However, while stem cells rely on glycolysis, different CSCs, including pancreatic CSCs, favor mitochondrial metabolism as their dominant energy-producing pathway. This suggests that powerful antioxidant networks must be in place to detoxify mitochondrial reactive oxygen species (ROS) and maintain stemness in oxidative CSCs. Since glutathione metabolism is critical for normal stem cell function and CSCs from breast, liver and gastric cancer show increased glutathione content, we hypothesized that pancreatic CSCs also rely on this pathway for ROS detoxification., [Aim]:To investigate the role of glutathione metabolism in pancreatic CSCs., [Methods]: Primary pancreatic cancer cells of patient-derived xenografts (PDXs) were cultured in adherent or CSC-enriching sphere conditions to determine the role of glutathione metabolism in stemness. Real-time polymerase chain reaction (PCR) was used to validate RNAseq results involving glutathione metabolism genes in adherent vs spheres, as well as the expression of pluripotency-related genes following treatment. Public TCGA and GTEx RNAseq data from pancreatic cancer vs normal tissue samples were analyzed using the webserver GEPIA2. The glutathione-sensitive fluorescent probe monochlorobimane was used to determine glutathione content by fluorimetry or flow cytometry. Pharmacological inhibitors of glutathione synthesis and recycling [buthionine-sulfoximine (BSO) and 6-Aminonicotinamide (6-AN), respectively] were used to investigate the impact of glutathione depletion on CSC-enriched cultures. Staining with propidium iodide (cell cycle), Annexin-V (apoptosis) and CD133 (CSC content) were determined by flow cytometry. Self-renewal was assessed by sphere formation assay and response to gemcitabine treatment was used as a readout for chemoresistance., [Results]:Analysis of our previously published RNAseq dataset E-MTAB-3808 revealed up-regulation of genes involved in the KEGG (Kyoto Encyclopedia of Genes and Genomes) Pathway Glutathione Metabolism in CSC-enriched cultures compared to their differentiated counterparts. Consistently, in pancreatic cancer patient samples the expression of most of these up-regulated genes positively correlated with a stemness signature defined by NANOG, KLF4, SOX2 and OCT4 expression (P < 10-5). Moreover, 3 of the upregulated genes (MGST1, GPX8, GCCT) were associated with reduced disease-free survival in patients [Hazard ratio (HR) 2.2-2.5; P = 0.03-0.0054], suggesting a critical role for this pathway in pancreatic cancer progression. CSC-enriched sphere cultures also showed increased expression of different glutathione metabolism-related genes, as well as enhanced glutathione content in its reduced form (GSH). Glutathione depletion with BSO induced cell cycle arrest and apoptosis in spheres, and diminished the expression of stemness genes. Moreover, treatment with either BSO or the glutathione recycling inhibitor 6-AN inhibited self-renewal and the expression of the CSC marker CD133. GSH content in spheres positively correlated with intrinsic resistance to gemcitabine treatment in different PDXs r = 0.96, P = 5.8 × 1011). Additionally, CD133+ cells accumulated GSH in response to gemcitabine, which was abrogated by BSO treatment (P < 0.05). Combined treatment with BSO and gemcitabine-induced apoptosis in CD133+ cells to levels comparable to CD133- cells and significantly diminished self-renewal (P < 0.05), suggesting that chemoresistance of CSCs is partially dependent on GSH metabolism., [Conclusion]: Our data suggest that pancreatic CSCs depend on glutathione metabolism. Pharmacological targeting of this pathway showed that high GSH content is essential to maintain CSC functionality in terms of self-renewal and chemoresistance., ERC Advanced Investigator Grant, No. Pa-CSC 233460; European Community's Seventh Framework Programme, No. 602783; Instituto de Salud Carlos III and European Funds (FSE: “el FSE invierte en tu futuro” and FEDER: “una manera de hacer Europa”) Miguel Servet Fellowship, No. CP16/00121; and Fondo Investigaciones Sanitarias, No. PI17/00082.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity

  • Zheng, Quan
  • Tang, Jiajia
  • Aicher, Alexandra
  • Bou Kheir, Tony
  • Sabanovic, Berina
  • Ananthanarayanan, Preeta
  • Reina, Chiara
  • Chen, Minchun
  • Gu, Jian-Min
  • He, Bin
  • Alcalá, Sonia
  • Behrens, Diana
  • Lawlor, Rita T.
  • Scarpa, Aldo
  • Hidalgo, Manuel
  • Sainz, Bruno Jr.
  • Sancho, Patricia
  • Heeschen, Christopher
[Background]; Pancreatic ductal adenocarcinoma (PDAC) is a profoundly aggressive and fatal cancer. One of the key factors defining its aggressiveness and resilience against chemotherapy is the existence of cancer stem cells (CSCs). The important task of discovering upstream regulators of stemness that are amenable for targeting in PDAC is essential for the advancement of more potent therapeutic approaches. In this study, we sought to elucidate the function of the nuclear receptor subfamily 5, group A, member 2 (NR5A2) in the context of pancreatic CSCs., [Methods]: We modeled human PDAC using primary PDAC cells and CSC-enriched sphere cultures. NR5A2 was genetically silenced or inhibited with Cpd3. Assays included RNA-seq, sphere/colony formation, cell viability/toxicity, real-time PCR, western blot, immunofluorescence, ChIP, CUT&Tag, XF Analysis, lactate production, and in vivo tumorigenicity assays. PDAC models from 18 patients were treated with Cpd3-loaded nanocarriers., [Results]: Our findings demonstrate that NR5A2 plays a dual role in PDAC. In differentiated cancer cells, NR5A2 promotes cell proliferation by inhibiting CDKN1A. On the other hand, in the CSC population, NR5A2 enhances stemness by upregulating SOX2 through direct binding to its promotor/enhancer region. Additionally, NR5A2 suppresses MYC, leading to the activation of the mitochondrial biogenesis factor PPARGC1A and a shift in metabolism towards oxidative phosphorylation, which is a crucial feature of stemness in PDAC. Importantly, our study shows that the specific NR5A2 inhibitor, Cpd3, sensitizes a significant fraction of PDAC models derived from 18 patients to standard chemotherapy. This treatment approach results in durable remissions and long-term survival. Furthermore, we demonstrate that the expression levels of NR5A2/SOX2 can predict the response to treatment., [Conclusions]: The findings of our study highlight the cell context-dependent effects of NR5A2 in PDAC. We have identified a novel pharmacological strategy to modulate SOX2 and MYC levels, which disrupts stemness and prevents relapse in this deadly disease. These insights provide valuable information for the development of targeted therapies for PDAC, offering new hope for improved patient outcomes., This work was supported by the ERC Advanced Investigator Grant (Pa-CSC 233460, to CH), the European Community's Seventh Framework Programme (FP7) under grant agreement n° 602783 (CAM-PaC, to CH), the Fondazione del Piemonte per l’Oncologia – IRCCS (PTCRC-Intra-2021 to CH), the Shanghai Municipal Education Commission (2021–01-07–00-02-E00090, to CH), the National Natural Science Foundation of China (82130074 and 82250710179 to CH; 81902673, to QZ), the Ministry of Science and Technology, Taiwan (Grant number MOST 111–2314-B-039–056, to AA), Shanghai Pujiang Program (21PJ1408900, to JT), Associazione Italiana Ricerca Cancro IG n. 26343 (A.S.), and Fondazione Italiana Malattie Pancreas – Ministero Salute FIMP_CUP J37G22000230001 (RTL)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells

  • López-Gil, Juan Carlos
  • García-Silva, Susana
  • Ruiz-Cañas, Laura
  • Navarro, Diego
  • Palencia-Campos, Adrián
  • Giráldez-Trujillo, Antonio
  • Earl, Julie
  • Dorado, Jorge
  • Gómez-López, Gonzalo
  • Monfort-Vengut, Ana
  • Alcalá, Sonia
  • Gaida, Matthias M.
  • García-Mulero, Sandra
  • Cabezas-Sainz, Pablo
  • Batres-Ramos, Sandra
  • Barreto, Emma
  • Sánchez-Tomero, Patricia
  • Vallespinós, Mireia
  • Ambler, Leah
  • Lin, Meng-Lay
  • Aicher, Alexandra
  • García García de Paredes, Ana
  • Pinta, Carolina De La
  • Sanjuanbenito, Alfonso
  • Ruz-Caracuel, Ignacio
  • Rodríguez-Garrote, Mercedes
  • Guerra, Carmen
  • Carrato, Alfredo
  • Cárcer, Guillermo de
  • Sánchez, Laura
  • Nombela-Arrieta, César
  • Espinet, Elisa
  • Sánchez-Arévalo Lobo, Víctor J.
  • Heeschen, Christopher
  • Sainz, Bruno Jr.
[Objective]: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant ‘stem-like’ cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies., [Design]: We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed., [Results]: Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNFα)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC., [Conclusions]: This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy., JCL-G received support from a ’la Caixa’ Foundation (ID 100010434) fellowship (LCF/BQ/DR21/11880011) and an EMBO Scientific Exchange Fellowship (ID 10210). AP-C was a recipient of a Juan de la Cierva Formación 2020 (FJC2020- 044220-I) grant. This study was supported by a Fero Foundation Grant (BSJr.) and Rámon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economía y Competitividad, Spain (BSJr.); received funding from the Beca Carmen Delgado/ Miguel Pérez-Mateo from AESPANC-ACANPAN Spain (BSJr), a Conquer Cancer Now Grant from the Concern Foundation (Los Angeles, CA, USA) (BSJr), a Coordinated grant (GC16173694BARB) from the Fundación Asociación Española Contra el Cáncer (AECC) (BSJr; AC), and FIS grants PI18/00757 and PI21/01110 (BSJr), PI19/00514 (CG) and PI22/00492 (VJSAL); and cofinanced through Fondo Europeo de Desarrollo Regional ’Una manera de hacer Europa’). We also acknowledge the support from CIBERONC (CB16/12/00446) (AC) and Ayudas de Consolidación y Estructuración de grupos from Consellería de Educación, Universidade y Formación profesional (ED431C-2028/28) and Programa de axudas á etapa posdotoral, both from Xunta de Galicia (LS, PCS). Projects were financed via MCIN/ AEI/FEDER (10.13039/501100011033) (REF-PID2021-125705OB-I00 (GdC) and REF-RTI2018- 095496-B-100) (GdC), and PID2021-124520OA-I00 and RYC2020-029767 (EE), and others including AECC (LABAE16017DECÁ, GdC and TRNSC213893ESPI, SG-M); the Clinical Research Priority Program ’ImmunoCure’ of the University of Zurich (CN-A), the German Research Foundation (SFB1292 Project Number 318346496, TPQ1 and TP22), GA1818/2-3 (MMG) as well as funding from an ERC Advanced Investigator Grant (Pa-CSC 233460, CH), the European Community’s Seventh Framework Programme (FP7) under grant agreement n° 602783 (CAM-PaC, CH), the Fondazione del Piemonte per l’Oncologia – IRCCS (PTCRC-Intra-2021, CH), the Fondazione AIRC per la ricerca sul cancro (IG 2023 ID 28933, CH), the Shanghai Municipal Education Commission (2021-01-07-00-02-E00090, CH), and the National Science Foundation China (82130074, CH)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer

  • Parejo-Alonso, Beatriz
  • Barneda, David
  • Trabulo, Sara Maria David
  • Courtois, Sarah
  • Compte-Sancerni, Sara
  • Zurkovic, Jelena
  • Ruiz-Cañas, Laura
  • Zheng, Quan
  • Tang, Jiajia
  • Gaida, Matthias M.
  • Schmitz, Ulf
  • Irun, Pilar
  • Penin-Peyta, Laure
  • Crusz, Shanthini Mary
  • Jagušt, Petra
  • Espiau-Romera, Pilar
  • Royo-García, Alba
  • Gordo-Ortiz, Andrés
  • Yuneva, Mariia
  • Lin, Meng-Lay
  • Huang, Shenghui
  • Yang, Ming-Hsin
  • Lanas, Angel
  • Sainz, Bruno Jr.
  • Thiele, Christoph
  • Heeschen, Christopher
  • Sancho, Patricia
The pronounced desmoplastic response in pancreatic ductal adenocarcinoma (PDAC) contributes to the development of a microenvironment depleted of oxygen and nutrients. To survive in this hostile environment, PDAC cells use various adaptive mechanisms that may represent therapeutic targets. In this study, we showed that nutrient starvation and microenvironmental signals commonly present in PDAC tumors activate PPARδ to rewire cellular metabolism and promote invasive and metastatic properties both in vitro and in vivo. Mild mitochondrial inhibition induced by low-dose etomoxir or signals from tumor-associated macrophages altered the lipidome and triggered the downstream transcriptional program of PPARδ. Specifically, PPARδ reduced mitochondrial oxygen consumption and boosted the glycolytic capacity by altering the ratio of MYC and PGC1A expression, two key regulators of pancreatic cancer metabolism. Notably, genetic or pharmacologic inhibition of PPARδ prevented this metabolic rewiring and suppressed both invasiveness in vitro and metastasis in vivo. These findings establish PPARδ as a central driver of metabolic reprogramming in response to starvation and tumor microenvironmental cues that promotes a prometastatic phenotype in PDAC, suggesting that PPARδ inhibition could serve as a therapeutic strategy to combat PDAC progression., The research was supported by the National Science Foundation of China (82130074 and 82250710179 to C. Heeschen), the Shanghai Municipal Education Commission (2021-01-07-00-02-E00090 to C. Heeschen), an ERC Advanced Investigator Grant (Pa-CSC 233460 to C. Heeschen), the European Community’s Seventh Framework Program (FP7/2007-2013) under grant agreement no. 602783 (CAM-PaC; to C. Heeschen), the FPRC 5 per mille Ministero della Salute 2017 PTCRC-Intra 2020 (to C. Heeschen), FPRC 5 per mille Ministero della Salute 2018 ADVANCE (to C. Heeschen); FPRC 5 per mille Ministero della Salute 2022 CARESS (to C. Heeschen), the Italian Ministry of Health, Ricerca Corrente 2025 (to C. Heeschen), the Fondazione AIRC per la ricerca sul cancro (IG 2023 ID 28933 to C. Heeschen), the Instituto de Salud Carlos III through the Miguel Servet Program (CP16/00121 and CPII21/00005 to P. Sancho), the predoctoral pFIS program (FI21/00031 to P. Espiau-Romera), Fondo de Investigaciones Sanitarias [PI17/00082 and PI20/00921 to P. Sancho; all cofinanced by European funds (FSE: “El FSE invierte en tu futuro” and FEDER: “Una manera de hacer Europa,” respectively)], the Worldwide Cancer Research Charity together with Fundación Científica de la Asociación Española contra el Cáncer (FCAECC; 19-0250 to P. Sancho), a predoctoral fellowship (PRDAR222458ROYO to A. Royo-García), a LAB AECC grant (LABAE223389SANC, to P. Sancho), and a coordinated grant (GC16173694BARB to B. Sainz, Jr.) all from the FCAECC, the Fero Foundation (to B. Sainz, Jr.), an Investigator Grant (NHMRC #1196405 to U. Schmitz), a Cancer Council NSW project grant (RG20-12 to U. Schmitz), and a German Research Foundation grant (318346496, SFB1292/2 TPQ1, TP22 to M.M. Gaida)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells

  • Jagust, P.
  • Alcalá, S.
  • Jr, B.S.
  • Heeschen, C.
  • Sancho, P.
BACKGROUND Cellular metabolism regulates stemness in health and disease. A reduced redox state is essential for self-renewal of normal and cancer stem cells (CSCs). However, while stem cells rely on glycolysis, different CSCs, including pancreatic CSCs, favor mitochondrial metabolism as their dominant energy-producing pathway. This suggests that powerful antioxidant networks must be in place to detoxify mitochondrial reactive oxygen species (ROS) and maintain stemness in oxidative CSCs. Since glutathione metabolism is critical for normal stem cell function and CSCs from breast, liver and gastric cancer show increased glutathione content, we hypothesized that pancreatic CSCs also rely on this pathway for ROS detoxification. AIM To investigate the role of glutathione metabolism in pancreatic CSCs. METHODS Primary pancreatic cancer cells of patient-derived xenografts (PDXs) were cultured in adherent or CSC-enriching sphere conditions to determine the role of glutathione metabolism in stemness. Real-time polymerase chain reaction (PCR) was used to validate RNAseq results involving glutathione metabolism genes in adherent vs spheres, as well as the expression of pluripotency-related genes following treatment. Public TCGA and GTEx RNAseq data from pancreatic cancer vs normal tissue samples were analyzed using the webserver GEPIA2. The glutathione-sensitive fluorescent probe monochlorobimane was used to determine glutathione content by fluorimetry or flow cytometry. Pharmacological inhibitors of glutathione synthesis and recycling [buthionine-sulfoximine (BSO) and 6-Aminonicotinamide (6-AN), respectively] were used to investigate the impact of glutathione depletion on CSC-enriched cultures. Staining with propidium iodide (cell cycle), Annexin-V (apoptosis) and CD133 (CSC content) were determined by flow cytometry. Self-renewal was assessed by sphere formation assay and response to gemcitabine treatment was used as a readout for chemoresistance. RESULTS Analysis of our previously published RNAseq dataset E-MTAB-3808 revealed up-regulation of genes involved in the KEGG (Kyoto Encyclopedia of Genes and Genomes) Pathway Glutathione Metabolism in CSC-enriched cultures compared to their differentiated counterparts. Consistently, in pancreatic cancer patient samples the expression of most of these up-regulated genes positively correlated with a stemness signature defined by NANOG, KLF4, SOX2 and OCT4 expression (P < 10-5). Moreover, 3 of the upregulated genes (MGST1, GPX8, GCCT) were associated with reduced disease-free survival in patients [Hazard ratio (HR) 2.2-2.5; P = 0.03-0.0054], suggesting a critical role for this pathway in pancreatic cancer progression. CSC-enriched sphere cultures also showed increased expression of different glutathione metabolism-related genes, as well as enhanced glutathione content in its reduced form (GSH). Glutathione depletion with BSO induced cell cycle arrest and apoptosis in spheres, and diminished the expression of stemness genes. Moreover, treatment with either BSO or the glutathione recycling inhibitor 6-AN inhibited self-renewal and the expression of the CSC marker CD133. GSH content in spheres positively correlated with intrinsic resistance to gemcitabine treatment in different PDXs r = 0.96, P = 5.8 × 1011). Additionally, CD133+ cells accumulated GSH in response to gemcitabine, which was abrogated by BSO treatment (P < 0.05). Combined treatment with BSO and gemcitabine-induced apoptosis in CD133+ cells to levels comparable to CD133- cells and significantly diminished self-renewal (P < 0.05), suggesting that chemoresistance of CSCs is partially dependent on GSH metabolism. CONCLUSION Our data suggest that pancreatic CSCs depend on glutathione metabolism. Pharmacological targeting of this pathway showed that high GSH content is essential to maintain CSC functionality in terms of self-renewal and chemoresistance.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk

  • Gomez-Rubio, P.
  • Piñero González, Janet, 1977-
  • Ilzarbe Sánchez, Lucas
  • Iglesias Coma, Mar
  • Poves Prim, José Ignacio
  • Real, Francisco X.
  • PanGenEU Study Investigators
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, many patients suffer or have suffered from other diseases. Identifying disease patterns associated with PDAC risk may enable a better characterization of high-risk patients. METHODS: Multimorbidity patterns (MPs) were assessed from 17 self-reported conditions using hierarchical clustering, principal component, and factor analyses in 1705 PDAC cases and 1084 controls from a European population. Their association with PDAC was evaluated using adjusted logistic regression models. Time since diagnosis of morbidities to PDAC diagnosis/recruitment was stratified into recent (<3 years) and long term (≥3 years). The MPs and PDAC genetic networks were explored with DisGeNET bioinformatics-tool which focuses on gene-diseases associations available in curated databases. RESULTS: Three MPs were observed: gastric (heartburn, acid regurgitation, Helicobacter pylori infection, and ulcer), metabolic syndrome (obesity, type-2 diabetes, hypercholesterolemia, and hypertension), and atopic (nasal allergies, skin allergies, and asthma). Strong associations with PDAC were observed for ≥2 recently diagnosed gastric conditions [odds ratio (OR), 6.13; 95% confidence interval CI 3.01-12.5)] and for ≥3 recently diagnosed metabolic syndrome conditions (OR, 1.61; 95% CI 1.11-2.35). Atopic conditions were negatively associated with PDAC (high adherence score OR for tertile III, 0.45; 95% CI, 0.36-0.55). Combining type-2 diabetes with gastric MP resulted in higher PDAC risk for recent (OR, 7.89; 95% CI 3.9-16.1) and long-term diagnosed conditions (OR, 1.86; 95% CI 1.29-2.67). A common genetic basis between MPs and PDAC was observed in the bioinformatics analysis. CONCLUSIONS: Specific multimorbidities aggregate and associate with PDAC in a time-dependent manner. A better characterization of a high-risk population for PDAC may help in the early diagnosis of this cancer. The common genetic basis between MP and PDAC points to a mechanistic link between these conditions., The work was partially supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III-FEDER, Spain (PI11/01542, PI0902102, PI12/01635, PI12/00815, PI13/00082, and CP10/00524); Red Tematica de Investigacion Cooperativa en Cancer, Spain (RD12/0036/0034, RD12/0036/0050, and RD12/0036/0073); World Cancer Research (WCR 15-0391); Accion Especial de Gen omica, Spain (GEN2001-4748-c05-03); EU-6FP Integrated Project (018771-MOLDIAG-PACA), EUFP7-HEALTH (259737-CANCERALIA, 256974-EPC-TM-Net, and 602783-Cam-Pac), Associazione Italiana Ricerca sul Cancro (AIRC 12182); Cancer Focus Northern Ireland and Department for Employment and Learning; ALF (SLL20130022), Sweden; Italian Foundation for Cancer Research (FIRC) (no grant numbers apply). The